The effective use of the correct medication can greatly improve the chance of remission for patients with acute myeloid leukemia…
Browsing: Acute Lymphoblastic Leukemia
Though women of childbearing age are diagnosed with myeloproliferative neoplasms (MPNs) less frequently than the general population, it is key…
Chronic inflammation is a key hallmark of myeloproliferative neoplasms (MPNs) and is responsible for many of the symptoms that affect…
To effectively treat acute myeloid leukemia (AML) in elderly patients, it is important that therapies for the right demographic are…
Thrombosis is a major risk factor for early mortality in patients with myeloproliferative neoplasms (MPNs), particularly essential thrombocythemia and polycythemia…
As patient awareness and knowledge of disease increases, the way in which doctors provide information to their patients in Spain…
Myeloproliferative neoplasms are complex diseases, with new research constantly updating our understanding of risk factors that may cause the diseases…
For relapsed and elderly acute myeloid leukemia patients, standard treatment is often not good enough. In this interview, Jorge Sierra,…
In this interview, Alessandro Vannucchi, MD, of the University of Florence, Florence, Italy, talks about the new models that doctors…
An advanced age can limit treatment options when tackling leukemia. Speaking from the International Conference on Acute Myeloid Leukaemia 2017,…
As alternatives to chemotherapy are created, the prospect of having treatments with a lower toxicity becomes more tangible. In this…
This is an exciting time for leukemia research, with the latest research using bispecifics revealing positive outcomes for patients. Here,…
The inflammation induced by medication can create challenges when producing novel treatments. In this interview, Prof. John DiPersio, MD, PhD…
It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients.…
As diseases mutate our knowledge of them increases. In this interview, Prof. John DiPersio, MD, PhD from Washington University School…
This is an exciting time for acute myeloid leukemia (AML) treatment, with multiple new therapies being investigated currently. In this…
Using uniform methods of detection allows for the efficient diagnosis of various ailments. In this interview, Francesco Lo-Coco, MD, from…
As treatment advancements are made, the number of people who cannot be treated effectively is reduced. In this interview, Francesco…
When considering which treatment to prescribe for acute myeloid leukemia (AML), an advanced age is a limiting factor. With recent…
There have been large strides in the treatment of leukemia; however, current methods lack specificity. Speaking from the International Conference…
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses how a novel molecule, S64315,…
There is some agreement within the multiple myeloma (MM) community regarding the importance of combination chemotherapy, transplant, personalized therapy and…
The evasion of apoptosis is a hallmark of cancer, which needs to be halted in order to treat malignancies. In…
As novel anticancer drugs undergo clinical trials and enter the market, patients with cancer are experiencing better outcomes and living…
Cancer nurses play a critical role in improving the quality of life and outcomes of patients. In this interview, recorded…
The UK Oncology Nursing Society (UKONS) Annual Conference 2017, held in Harrogate, UK, had the central theme of person-centered care.…
With the NHS being stretched considerably in terms of its budget and increasing pressure placed upon its staff, any strategies…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the affordability of cancer treatments at the 2017…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses novel conceptual treatment approaches at the 2017 International…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the evolution of CAR T-cell therapy at the…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses highlights of the 2017 International Workshop in Non-Hodgkin…
Michael Pfreundschuh, MD from the Saarland University, Homburg, Germany is joined by Ryan Morin, PhD from the BC Cancer Agency,…
Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY is joined by Eduardo Sotomayor, MD, from…
Catherine Bollard, MBChB, MD, FRACP, FRCPA from the Childrens National Health System and the George Washington University, Washington, D.C. chairs…
Philippe Gaulard, MD, PhD, from the Henri-Mondor Hospital, Paris, France, Francesco DAmore, MD, PhD, from the Aarhus University, Aarhus, Denmark,…
Patients with myeloproliferative neoplasm (MPNs) are at a higher risk of mortality due to thrombosis compared with unaffected individuals. Speaking…
In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from…
Around a quarter of new amyloidosis patients die within 6 months of diagnosis, and, despite large pharmacological and technological advancements,…
There are two primary routes of therapy for amyloidosis: treating the underlying plasma cell dyscrasia, and clearing amyloid deposits. In…
Key to the treatment of amyloidosis is being able to discern the severity of illness, so that the patient can…
Prostate cancer therapies have developed greatly in recent years, with many more options for treatment available that can provide patients…
A clinical nurse specialist plays a critical role in the treatment of a cancer patient. In this interview, Hilary Baker…
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses side effects of PI3K inhibitors…
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas…
Marek Trneny, MD, from the Charles University, Prague, Czech Republic, discusses highlights from the International Workshop on Non-Hodgkin Lymphoma (iwNHL)…
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses integrating treatments around autologous transplantation at the…
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International…
The exciting field of proton beam therapy is still developing; thus, as its utilization in the UK increases there is…
The introduction of new healthcare tools requires the careful navigation of social, political and economic pressures. In this interview, recorded…